The production of cell therapies requires optimizing scalability of biological materials which are innately variable. While undertaking these complexities, our team has been developing scalable processes for more than a decade. Our expertise spans a multitude of cell types for both autologous and allogeneic therapy development.
The most critical value of our development program is our commitment to establish commercial-ready processes early in order to streamline the transition of your program from clinical to commercial manufacturing. With cell therapy products moving at an accelerated pace within the clinical pipeline, timelines for development and manufacturing are also compressed, requiring quick expert decision making in the early development phases. At Catalent, we are focused on speed, simplicity, and reproducibility as we develop your custom program to give you an advantage going into the clinic. Our team of highly dedicated experts combines their robust experience in CGMP manufacturing with a technology-focused approach to enable you to reach your milestones quicker and more efficiently.